Summary:
Columbus Clinical Research is conducting a Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients with Chronic Migraine
Qualified Participants Must:
• Be between the ages of 18 and 55
•
Experience 15 or more days with headaches in a month
Qualified Participants May Receive:
All study related care and Compensation for their time and travel may be available.